1312704-84-9

Basic information

• Product Name: 1-(4-chloro-2-(trifluoroMethyl)benzyl)-1H-indazole-5-carbaldehyde
• Synonyms: 1-(4-chloro-2-(trifluoroMethyl)benzyl)-1H-indazole-5-carbaldehyde
• CAS NO: 1312704-84-9
• Molecular Weight: 338.716
• Mol File: 1312704-84-9.mol
• Article Data: 6

Chemical Properties

• CAS DataBase Reference: 1-(4-chloro-2-(trifluoroMethyl)benzyl)-1H-indazole-5-carbaldehyde(CAS DataBase Reference)
• NIST Chemistry Reference: 1-(4-chloro-2-(trifluoroMethyl)benzyl)-1H-indazole-5-carbaldehyde(1312704-84-9)
• EPA Substance Registry System: 1-(4-chloro-2-(trifluoroMethyl)benzyl)-1H-indazole-5-carbaldehyde(1312704-84-9)

Safety Data

• Hazardous Substances Data: 1312704-84-9(Hazardous Substances Data)

Usage

General Description

1-(4-chloro-2-(trifluoroMethyl)benzyl)-1H-indazole-5-carbaldehyde is a chemical compound that belongs to the class of indazole derivatives. It is a benzyl-substituted indazole derivative with a chloro and trifluoroMethyl substituent on the benzyl ring. The compound contains a carbaldehyde functional group attached to the indazole ring, and it is commonly used in medicinal chemistry, particularly in the development of pharmaceuticals and agrochemicals. Due to its structural features, the compound exhibits potential biological activities and may act as an intermediate in the synthesis of various organic compounds. Its chemical properties make it a valuable tool in research and drug discovery efforts.

Upstream product

• 253801-04-6 1H-indazole-5-carbaldehyde 
• 886496-75-9 1-(bromomethyl)-4-chloro-2-(trifluoromethyl)benzene 
• 1086391-08-3 3-bromo-1H-indazole-5-carbaldehyde 

Downstream Products

• 1548129-20-9 C₂₉H₂₇ClF₄N₄O₄S 
• 1351571-37-3 (5Z)-5-({1-[4-chloro-2-(trifluoromethyl)benzyl]-1H-indazol-5-yl}methylidene)-3-[(3R,4R)-3-fluoropiperidin-4-yl]-1,3-thiazolidine-2,4-dione 
• 1548128-70-6 C₂₉H₂₈ClF₃N₄O₅S 
• 1548128-74-0 C₂₉H₂₈ClF₃N₄O₅S 
• 1351569-83-9 C₁₉H₁₁ClF₃N₃O₂S 
• 1548129-12-9 C₂₉H₂₇ClF₄N₄O₄S 
• 1351571-42-0 (5Z)-5-({1-[4-chloro-2-(trifluoromethyl)benzyl]-1H-indazol-5-yl}methylidene)-3-(3R,4R)-(3-fluoro-1-methylpiperidin-4-yl)-1,3-thiazolidine-2,4-dione 
• 1548129-04-9 (Z)-5-((1-(4-chloro-2-(trifluoromethyl)benzyl)-1H-indazol-5-yl)methylene)-3-((3R,4R)-3-fluoro-1-methylpiperidin-4-yl)thiazolidine-2,4-dione hydrochloride salt 
• 1351571-43-1 (5Z)-5-({1-[4-chloro-2-(trifluoromethyl)benzyl]-1H-indazol-5-yl}methylidene)-3-(3S,4S)-(3-fluoro-1-methylpiperidin-4-yl)-1,3-thiazolidine-2,4-dione 
• 1351620-78-4 4-[(5Z)-5-({1-[4-chloro-2-(trifluoromethyl)benzyl]-1Hindazol-5-yl}methylidene)-2,4-dioxo-1,3-thiazolidin-3-yl]cyclohexanecarboxylic acid 
• 1351567-46-8 3-[(2S)-2-aminopropyl]-(5Z)-5-({1-[4-chloro-2-(trifluoromethyl)benzyl]-1H-indazol-5-yl}methylidene)-1,3-thiazolidine-2,4-dione 

Relevant articles and documents

Indazole-based ligands for estrogen-related receptor α as potential anti-diabetic agents

Estrogen-related receptor α (ERRα) is an orphan nuclear receptor that has been functionally implicated in the regulation of energy homeostasis. Herein is described the development of indazole-based N-alkylthiazolidenediones, which function in biochemical

SUBSTITUTED AMINOTHIAZOLONE INDAZOLES AS ESTROGEN RELATED RECEPTOR-ALPHA MODULATORS

The present invention relates to compounds of Formula (I), methods for preparing these compounds, compositions, intermediates and derivatives thereof and for treating a condition including but not limited to ankylosing spondylitis, artherosclerosis, arthritis (such as rheumatoid arthritis, infectious arthritis, childhood arthritis, psoriatic arthritis, reactive arthritis), bone-related diseases (including those related to bone formation), breast cancer (including those unresponsive to anti-estrogen therapy), cardiovascular disorders, cartilage-related disease (such as cartilage injury/loss, cartilage degeneration, and those related to cartilage formation), chondrodysplasia, chondrosarcoma, chronic back injury, chronic bronchitis, chronic inflammatory airway disease, chronic obstructive pulmonary disease, diabetes, disorders of energy homeostasis, gout, pseudogout, lipid disorders, metabolic syndrome, multiple myeloma, obesity, osteoarthritis, osteogenesis imperfecta, osteolytic bone metastasis, osteomalacia, osteoporosis, Paget's disease, periodontal disease, polymyalgia rheumatica, Reiter's syndrome, repetitive stress injury, hyperglycemia, elevated blood glucose level, and insulin resistance.

AMINOTHIAZOLONES AS ESTROGEN RELATED RECEPTOR-ALPHA MODULATORS

The present invention relates to compounds of Formula (I), methods for preparing these compounds, compositions, intermediates and derivatives thereof and for treating a condition including but not limited to ankylosing spondylitis, artherosclerosis, arthritis (such as rheumatoid arthritis, infectious arthritis, childhood arthritis, psoriatic arthritis, reactive arthritis), bone-related diseases (including those related to bone formation), breast cancer (including those unresponsive to anti-estrogen therapy), cardiovascular disorders, cartilage-related disease (such as cartilage injury/loss, cartilage degeneration, and those related to cartilage formation), chondrodysplasia, chondrosarcoma, chronic back injury, chronic bronchitis, chronic inflammatory airway disease, chronic obstructive pulmonary disease, diabetes, disorders of energy homeostasis, gout, pseudogout, lipid disorders, metabolic syndrome, multiple myeloma, obesity, osteoarthritis, osteogenesis imperfecta, osteolytic bone metastasis, osteomalacia, osteoporosis, Paget's disease, periodontal disease, polymyalgia rheumatica, Reiter's syndrome, repetitive stress injury, hyperglycemia, elevated blood glucose level, and insulin resistance.